These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 2869319)
1. Rationale for early use of levodopa in parkinsonism. Pincus JH Lancet; 1986 Mar; 1(8481):612-3. PubMed ID: 2869319 [No Abstract] [Full Text] [Related]
2. Systemic activity of orally administered L-dopa in the elderly Parkinson patient. Evans MA; Triggs EJ; Broe GA; Saines N Eur J Clin Pharmacol; 1980; 17(3):215-21. PubMed ID: 7363934 [No Abstract] [Full Text] [Related]
4. Drug therapy of parkinsonism. Bianchine JR N Engl J Med; 1976 Oct; 295(15):814-8. PubMed ID: 958277 [No Abstract] [Full Text] [Related]
5. Parkinsonism: forgotten considerations in medical treatment and nursing care. Garrett E J Neurosurg Nurs; 1982 Feb; 14(1):13-8. PubMed ID: 6918437 [No Abstract] [Full Text] [Related]
6. Parkinsonism and long-term levodopa. Caraceni T Neurology; 1980 Oct; 30(10):1136-7. PubMed ID: 7191508 [No Abstract] [Full Text] [Related]
7. [Effects and side effects of levodopa in parkinsonism - results of a collaborative study. (6) Problems of long-term treatment of levodopa in parkinsoism]. Uono K Rinsho Shinkeigaku; 1976 Dec; 16(12):881-2. PubMed ID: 828568 [No Abstract] [Full Text] [Related]
8. Problems in the contemporary treatment of parkinsonism. Eadie MJ Med J Aust; 1985 Jan; 142(2):113-7. PubMed ID: 2981393 [No Abstract] [Full Text] [Related]
9. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. Nutt JG; Woodward WR; Hammerstad JP; Carter JH; Anderson JL N Engl J Med; 1984 Feb; 310(8):483-8. PubMed ID: 6694694 [TBL] [Abstract][Full Text] [Related]
13. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism. Pinder RM; Brogden RN; Sawyer PR; Speight TM; Avery GS Drugs; 1976; 11(5):329-77. PubMed ID: 782834 [No Abstract] [Full Text] [Related]
14. [Long-term treatment of middle-aged and old patients with paralysis agitans and parkinsonism with levodopa]. Bogolepov NK; Gorbunov FE Vrach Delo; 1975 Aug; (8):126-30. PubMed ID: 1221589 [No Abstract] [Full Text] [Related]
15. The history of dopamine and levodopa in the treatment of Parkinson's disease. Fahn S Mov Disord; 2008; 23 Suppl 3():S497-508. PubMed ID: 18781671 [TBL] [Abstract][Full Text] [Related]
17. Levodopa-responsive parkinsonism associated with hydrocephalus. Kim MJ; Chung SJ; Sung YH; Lee MC; Im JH Mov Disord; 2006 Aug; 21(8):1279-81. PubMed ID: 16639728 [TBL] [Abstract][Full Text] [Related]
18. Plasma DOPA and growth hormone in parkinsonism: oscillations in symptoms. Papavasiliou PS; McDowell FH; Wang YY; Rosal V; Miller ST Neurology; 1979 Feb; 29(2):194-200. PubMed ID: 571063 [TBL] [Abstract][Full Text] [Related]
19. [Risks of modern therapy for parkinsonism, and their consequences (author's transl)]. Jörg J; Kleine D Nervenarzt; 1979 Jan; 50(1):33-42. PubMed ID: 424033 [No Abstract] [Full Text] [Related]
20. Combined bromocriptine-levodopa therapy early in Parkinson's disease. Rinne UK Neurology; 1985 Aug; 35(8):1196-8. PubMed ID: 4022354 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]